Areas covered: In this review, we summarize the latest clinical study results on ixekizumab. Long-term Phase III study data on efficacy and safety are now available for both plaque psoriasis and psoriatic arthritis.
In addition to the interventions discussed in the update, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved apremilast and secukinumab as new treatment options for psoriasis.
Ixekizumab (Taltz®) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA).
The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use of biologic therapies targeting tumour necrosis factor (TNF)...
Background: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis.
Eli Lilly and Company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has...
Objective: This review aims to summarize the current efficacy data from phase II randomized controlled trials of the IL-17 antagonists brodalumab, ixekizumab, and secukinumab for the treatment of moderate to severe psoriasis.
Eli Lilly and Company has announced that the FDA has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of...
Background: Safety of biologics is important when treating patients with psoriasis. Objective: We sought to determine the safety of ixekizumab in psoriasis.
Introduction: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis.